Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3810929 | 0.97 | NR1H4 (0.48) | NR1H4SLC10A2 | |
| SCHEMBL14559699 | 0.97 | NR1H4 (0.48) | NR1H4SLC10A2 | |
| SCHEMBL6632483 | 0.95 | NR1H4 (0.47) | NR1H4SLC10A2 | |
| SCHEMBL5226375 | 0.95 | NR1H4 (0.46) | NR1H4SLC10A2 | |
| SCHEMBL23375139 | 0.93 | NR1H4 (0.50) | NR1H4SLC10A2 | |
| SCHEMBL14540326 | 0.93 | NR1H4 (0.50) | NR1H4SLC10A2 | |
| SCHEMBL27424458 | 0.93 | NR1H4 (0.44) | NR1H4SLC10A2 | |
| SCHEMBL23375099 | 0.93 | NR1H4 (0.43) | NR1H4SLC10A2 | |
| SCHEMBL5222558 | 0.93 | NR1H4 (0.43) | NR1H4SLC10A2 | |
| SCHEMBL23375114 | 0.92 | NR1H4 (0.44) | NR1H4SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | claimed |
| WO-2021110887-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | claimed |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2021-05-25 | — | — | US | claimed |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| CN-115175918-A | Method for manufacturing 1,5-benzothiazepine compound | 埃洛比克斯股份公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-09-30 | — | — | US | disclosed |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | disclosed |
| WO-2021110887-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-10995115-B2 | Process for the preparation of 1,5-benzothiazepine compounds | ELOBIX AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-10995115-B2 | Process for the preparation of 1,5-benzothiazepine compounds | ELOBIX AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-7192946-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-7192945-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20050222120-A1 | Peptides derivatives comprising thiazepine group for the treatment of hyperlipidermic conditions | ELOBIX AB (SE) | 2005-10-06 | — | — | US | disclosed |
| US-20040254160-A1 | Benzothiazepine derivatives | ELOBIX AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1430040-A1 | BENZOTHIAZEPINE DERIVATIVES | Astrazeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003020710-A1 | BENZOTHIAZEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885SLC10A2 2/4885 |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885SLC10A2 2/4885 |
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | NR1H4 7/4885SLC10A2 1/4885 |
| US-20050222120-A1 | Peptides derivatives comprising thiazepine group for the treatment of hyperlipidermic conditions | SLC10A2, SLC10A1, ABCB11 | NR1H4 7/4885SLC10A2 1/4885 |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885SLC10A2 2/4885 |
| US-10995115-B2 | Process for the preparation of 1,5-benzothiazepine compounds | CYP4B1, CYP3A5, CYP4X1 | NR1H4 1464/4885SLC10A2 463/4885 |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885SLC10A2 2/4885 |
| US-20040254160-A1 | Benzothiazepine derivatives | SLC10A2, SLC10A1, ABCB11 | NR1H4 6/4885SLC10A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.